196 related articles for article (PubMed ID: 26187258)
1. Cell substrates for the production of viral vaccines.
Aubrit F; Perugi F; Léon A; Guéhenneux F; Champion-Arnaud P; Lahmar M; Schwamborn K
Vaccine; 2015 Nov; 33(44):5905-12. PubMed ID: 26187258
[TBL] [Abstract][Full Text] [Related]
2. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases.
Barrett PN; Terpening SJ; Snow D; Cobb RR; Kistner O
Expert Rev Vaccines; 2017 Sep; 16(9):883-894. PubMed ID: 28724343
[TBL] [Abstract][Full Text] [Related]
3. Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production.
Tapia F; Vázquez-Ramírez D; Genzel Y; Reichl U
Appl Microbiol Biotechnol; 2016 Mar; 100(5):2121-32. PubMed ID: 26758296
[TBL] [Abstract][Full Text] [Related]
4. Bioreactor concepts for cell culture-based viral vaccine production.
Gallo-Ramírez LE; Nikolay A; Genzel Y; Reichl U
Expert Rev Vaccines; 2015; 14(9):1181-95. PubMed ID: 26178380
[TBL] [Abstract][Full Text] [Related]
5. Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines.
Hess RD; Weber F; Watson K; Schmitt S
Vaccine; 2012 Apr; 30(17):2715-27. PubMed ID: 22342707
[TBL] [Abstract][Full Text] [Related]
6. Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.
Rodrigues AF; Soares HR; Guerreiro MR; Alves PM; Coroadinha AS
Biotechnol J; 2015 Sep; 10(9):1329-44. PubMed ID: 26212697
[TBL] [Abstract][Full Text] [Related]
7. Matrix and backstage: cellular substrates for viral vaccines.
Jordan I; Sandig V
Viruses; 2014 Apr; 6(4):1672-700. PubMed ID: 24732259
[TBL] [Abstract][Full Text] [Related]
8. Vaccine process technology.
Josefsberg JO; Buckland B
Biotechnol Bioeng; 2012 Jun; 109(6):1443-60. PubMed ID: 22407777
[TBL] [Abstract][Full Text] [Related]
9. Vaccine provision: Delivering sustained & widespread use.
Preiss S; Garçon N; Cunningham AL; Strugnell R; Friedland LR
Vaccine; 2016 Dec; 34(52):6665-6671. PubMed ID: 27884478
[TBL] [Abstract][Full Text] [Related]
10. Novel vaccine strategies against emerging viruses.
García-Sastre A; Mena I
Curr Opin Virol; 2013 Apr; 3(2):210-6. PubMed ID: 23477832
[TBL] [Abstract][Full Text] [Related]
11. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.
Barrett PN; Mundt W; Kistner O; Howard MK
Expert Rev Vaccines; 2009 May; 8(5):607-18. PubMed ID: 19397417
[TBL] [Abstract][Full Text] [Related]
12. Plant-based vaccines against viruses.
Rybicki EP
Virol J; 2014 Dec; 11():205. PubMed ID: 25465382
[TBL] [Abstract][Full Text] [Related]
13. Fish vaccine antigens produced or delivered by recombinant DNA technologies.
Leong JC; Anderson E; Bootland LM; Chiou PW; Johnson M; Kim C; Mourich D; Trobridge G
Dev Biol Stand; 1997; 90():267-77. PubMed ID: 9270855
[TBL] [Abstract][Full Text] [Related]
14. Production of viral vaccines for veterinary use.
van Gelder P; Makoschey B
Berl Munch Tierarztl Wochenschr; 2012; 125(3-4):103-9. PubMed ID: 22515027
[TBL] [Abstract][Full Text] [Related]
15. Critical review of current and emerging quantification methods for the development of influenza vaccine candidates.
Manceur AP; Kamen AA
Vaccine; 2015 Nov; 33(44):5913-9. PubMed ID: 26271833
[TBL] [Abstract][Full Text] [Related]
16. Development and strategies of cell-culture technology for influenza vaccine.
Feng SZ; Jiao PR; Qi WB; Fan HY; Liao M
Appl Microbiol Biotechnol; 2011 Feb; 89(4):893-902. PubMed ID: 21063703
[TBL] [Abstract][Full Text] [Related]
17. Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges.
Delrue I; Verzele D; Madder A; Nauwynck HJ
Expert Rev Vaccines; 2012 Jun; 11(6):695-719. PubMed ID: 22873127
[TBL] [Abstract][Full Text] [Related]
18. Designing cell lines for viral vaccine production: Where do we stand?
Genzel Y
Biotechnol J; 2015 May; 10(5):728-40. PubMed ID: 25903999
[TBL] [Abstract][Full Text] [Related]
19. Plant-based vaccines: novel and low-cost possible route for Mediterranean innovative vaccination strategies.
Aboul-Ata AA; Vitti A; Nuzzaci M; El-Attar AK; Piazzolla G; Tortorella C; Harandi AM; Olson O; Wright SA; Piazzolla P
Adv Virus Res; 2014; 89():1-37. PubMed ID: 24751193
[TBL] [Abstract][Full Text] [Related]
20. Vaccine manufacturing: challenges and solutions.
Ulmer JB; Valley U; Rappuoli R
Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
